Abstract:  Triple-negative breast cancer (TNBC) is histologically defined by a lack of estrogen receptor and progesterone receptor expression and the absence of human epidermal growth factor receptor 2 overexpression and/or amplification, accounting for 10%-20% of all diagnosed breast cancers. As a group, patients with TNBC have a relatively poor outcome, including high incidence of relapse, early metastasis and poor effect of chemotherapy in advanced stage, and are more prone to visceral metastasis, especially lung and brain metastases. Compared with other subtypes of breast cancer, TNBC are frequently of higher histologic grade and poorer prognosis, which has always been the focus and difficulty of clinical research. In the era of precision medicine, with the application of gene detection technology, the classification of TNBC is more accurate, and there are many kinds of treatment, such as targeted therapy and immunotherapy. This review described the latest development in TNBC.

Key words: Triple-negative breast cancer, Precision medicine, Targeted therapy, Immunotherapy